Compare Ginkgo Bioworks Holdings Inc (DNA) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Wells Fargo & Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.55 (market cap $515.15M), while Wells Fargo & Co trades at $87.68 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 513.8× Ginkgo Bioworks Holdings Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | WFC | |
|---|---|---|
Market Cap | $515.15M | $264.66B |
Sector | Health | Financials |
52-Week High | $16.14 | $96.40 |
52-Week Low | $5.48 | $73.42 |
Enterprise Value | $617.10M | — |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
Wells Fargo (WFC) trades at $87.25, down 0.4% today, with a bullish technical outlook from moving averages and a consensus price target of $97.64. The stock shows strong profitability with a net income margin of 25.97% and ROE of 13.13%, supported by steady revenue growth to $83.70 billion in 2025. Recent news highlights the launch of tokenized deposits for corporate clients, reflecting innovation in digital banking services.
The stock presents a value opportunity with a P/E of 12.68, but risks include volatile cash flows and recent earnings misses. Upside is driven by analyst optimism and dividend increases, while headwinds involve economic sensitivity and competitive pressures in banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
